Executive Interview – Mologen

Executive Interview – Mologen

Mologen is a German biotech company developing cancer immunotherapies. Its lead product is lefitolimod (MGN1703), which is being tested in a Phase III trial for metastatic colorectal cancer (mCRC) and a Phase II trial in small cell lung cancer (SCLC). Lefitolimod is also in a Phase I trial for HIV and a combination trial with Yervoy, an immune checkpoint inhibitor.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free